NOPAIN for Veterans Act
Sponsored By: Representative Landsman
In Committee
Summary
Guarantees VA will add FDA‑approved non‑opioid pain drugs to its national formulary for veterans. This bill would define those drugs as FDA‑approved treatments that reduce postoperative pain or provide postsurgical or regional analgesia without acting on opioid receptors and set clear deadlines for VA to add them.
Show full summary
- Veterans and families: Would expand access to FDA‑approved non‑opioid postoperative and regional pain treatments, giving more options to manage pain without opioids.
- VA providers and the VA system: Would require the Secretary of Veterans Affairs to add eligible drugs to the VA national formulary and the VA drug standardization list within 90 days after enactment, and to add any drug that later becomes eligible for certain Medicare payment statuses within one year of that eligibility.
- Funding oversight: Bars using funds from the Cost of War Toxic Exposures Fund to carry out these changes.
Bill Overview
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
More non-opioid pain drugs for veterans
If enacted, the bill would require VA to add certain FDA‑cleared non‑opioid drugs and biologicals for postoperative or regional pain to its national formulary. The rule defines qualifying products as FDA approved, granted, or cleared for postoperative or postsurgical/regional analgesia that do not act on opioid receptors. VA would have to include a qualifying product in its formulary within one year after that product becomes eligible for certain Medicare payment rules, and the Secretary must implement the bill's changes within 90 days of enactment. The bill would bar using money from the Cost of War Toxic Exposures Fund to carry out these changes.
Sponsors & CoSponsors
Sponsor
Landsman
OH • D
Cosponsors
Van Orden
WI • R
Sponsored 7/17/2025
Pappas
NH • D
Sponsored 7/17/2025
Bergman
MI • R
Sponsored 7/17/2025
Sewell
AL • D
Sponsored 7/17/2025
Hamadeh (AZ)
AZ • R
Sponsored 7/17/2025
Khanna
CA • D
Sponsored 7/25/2025
Stanton
AZ • D
Sponsored 10/3/2025
Suozzi
NY • D
Sponsored 10/8/2025
Craig
MN • D
Sponsored 10/8/2025
Pettersen
CO • D
Sponsored 10/31/2025
Morrison
MN • D
Sponsored 11/7/2025
Del. Norton, Eleanor Holmes [D-DC-At Large]
DC • D
Sponsored 11/21/2025
McBride
DE • D
Sponsored 12/1/2025
Kennedy (NY)
NY • D
Sponsored 12/5/2025
Ciscomani
AZ • R
Sponsored 12/9/2025
DelBene
WA • D
Sponsored 12/11/2025
Schmidt
KS • R
Sponsored 12/19/2025
Harrigan
NC • R
Sponsored 1/12/2026
Thanedar
MI • D
Sponsored 1/22/2026
Morelle
NY • D
Sponsored 2/11/2026
Vindman
VA • D
Sponsored 2/23/2026
Kiggans (VA)
VA • R
Sponsored 2/26/2026
Roll Call Votes
No roll call votes available for this bill.
View on Congress.govRelated Bills
HR842 — Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Would expand Medicare to cover multi-cancer early detection screening tests. It defines eligible tests as certain FDA-cleared or approved genomic blood tests or comparable biological-sample tests and directs the Secretary to use the national coverage determinations process to decide when they are covered.
HR1262 — Mikaela Naylon Give Kids a Chance Act
Speeds and strengthens pediatric cancer drug development. It expands which cancer products companies must study in children, reshapes organ transplant network governance and fees, and adds new FDA international and transparency steps. - Children with cancer and researchers: Requires pediatric studies that produce clinically meaningful data on dosing, safety, and early effectiveness and widens the kinds of drug combinations studied. It also sets aside $25 million for pediatric drug studies in each of fiscal years 2026, 2027, and 2028. - Transplant patients and transplant network members: Changes Organ Procurement and Transplantation Network governance and financing by allowing quarterly registration fees, requiring those fees fund OPTN operations, improving electronic health record integration, and calling for a GAO review within two years. - FDA partners and drug makers: Creates an Abraham Accords Office to boost regulatory coordination and technical assistance abroad, and forces more transparency during generic (ANDA) reviews about whether generics are qualitatively and quantitatively the same as listed drugs. It also raises the Medicare Improvement Fund amount from $1.4 billion to $2.6 billion. Increases federal outlays by roughly $1.3 billion, driven by a $1.2 billion boost to the Medicare Improvement Fund and $75 million for pediatric studies, adding to federal spending.
HR2102 — Major Richard Star Act
Establishes concurrent receipt for retirees with combat-related disabilities. This bill would let eligible retirees receive both military retired pay and veterans' disability compensation for the same months without the offset rules that currently reduce payments. - Families of disabled retirees: Veterans with combat-related disabilities would receive both retired pay and VA disability compensation for the same months, increasing their monthly household income. - Defense and VA payment rules: The bill would amend 10 U.S.C. 1413a and 10 U.S.C. 1414 to exempt retired pay from reductions under 38 U.S.C. 5304 and 5305 and add a clear monthly no-offset rule. - Implementation and technical changes: It renames and updates chapter sections, adjusts cross-references, and applies to payments beginning the first month after enactment.
HR909 — Crime Victims Fund Stabilization Act of 2025
Would make the False Claims Act apply to deposits to the Crime Victims Fund through FY2029. It would also require an Inspector General audit that sets the audit's scope, timing, and recipients, and the measure is titled the Crime Victims Fund Stabilization Act of 2025. - Entities that make deposits to the Crime Victims Fund would be subject to the False Claims Act (31 U.S.C. 3729–3731) for deposits from enactment through FY2029. - An Inspector General audit would examine the Crime Victims Fund and the bill would set the audit's scope, timing, and who receives the report.
HR4206 — CONNECT for Health Act of 2025
Expands Medicare telehealth access by removing geographic limits and ending an in-person requirement for telemental health. It would also change payment rules for clinics and require more oversight, training, and data reporting. - Medicare beneficiaries would be able to receive telehealth across geographies beginning October 1, 2025. Telemental health would no longer require a six-month in-person visit and tribal and Native Hawaiian facilities would be exempt from originating-site rules starting January 1, 2026. - Federally Qualified Health Centers and Rural Health Clinics would be paid for telehealth under outpatient or prospective payment methods and telehealth costs as distant-site care would count as allowable PPS costs. The HHS Secretary could waive limits on which practitioner types may furnish telehealth starting October 1, 2025 with annual public comment and a three-year reassessment requirement. - The bill would strengthen program integrity funding for telehealth, require CMS to post quarterly telehealth data, and add telehealth to quality-measure reviews within 180 days. It also mandates a beneficiary engagement study and a Government Accountability Office report on hospice recertification within three years.
HR3514 — Improving Seniors’ Timely Access to Care Act of 2025
Standardize prior authorization in Medicare Advantage plans to make approvals faster and more transparent for beneficiaries and providers. The bill would require plans that use prior authorization to adopt a secure electronic PA program, publish plan-level PA data, and follow federal timeframes and enrollee protections.
Take It Personal
Get Your Personalized Policy View
Create a free account to save research, track policy impacts, and unlock your personalized versions of these pages.
Already have an account? Sign in